

**RPG LIFE SCIENCES LIMITED**

Regd. Off.: RPG House
463, Dr. Annie Besant Road
Worli, Mumbai 400030, India
Tel: +91-22-24981650 / 66606375
Fax: +91-22-24970127
Email: info@rpglifesciences.com
www.rpglifesciences.com
CIN : L24232MH2007PLC169354

July 25, 2025

To,

The Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, 5th Floor
Plot No. C1, 'G' Block, Bandra-Kurla Complex
Bandra (East), Mumbai 400 051.

BSE Limited
Corporate Relationship Department
Floor 25, P.J. Towers
Dalal Street
Mumbai 400 001.

Symbol: RPGLIFE

Scrip code: 532983

Dear Sirs,

Sub: Investor Presentation - Financial Results

Please find enclosed herewith a copy of Investor Presentation with respect to Unaudited Financial Results of the Company for the quarter ended June 30, 2025.

Kindly take the above on record.

Thanking you,

Yours faithfully,
For RPG Life Sciences Limited

Rajesh Shirambekar
Head – Legal & Company Secretary

Encl: as above



An  **RPG** Company

**Investors'
Presentation
Q1 FY26**

Disclaimer

This presentation may include statements which may constitute forward-looking statements. All statements that address expectations or projections about the future, including, but not limited to, statements about the strategy for growth, business development, market position, expenditures, and financial results, are forward looking statements. Forward looking statements are based on certain assumptions and expectations of future events. The Company cannot guarantee that these assumptions and expectations are accurate or will be realized. The actual results, performance or achievements, could thus differ materially from those projected in any such forward-looking statements.

The company operates in the Pharmaceutical segment. Some of the historical Profit and loss numbers which are sliced in the investor presentation for certain sales divisions are purely for broader understanding for investors of the business of the company and its growth trajectory. The information contained in these materials has not been independently verified. None of the Company, its Directors, Promoter or affiliates, nor any of its or their respective employees, advisers or representatives or any other person accepts any responsibility or liability whatsoever, whether arising in tort, contract or otherwise, for any errors, omissions or inaccuracies in such information or opinions or for any loss, cost or damage suffered or incurred howsoever arising, directly or indirectly, from any use of this document or its contents or otherwise in connection with this document, and makes no representation or warranty, express or implied, for the contents of this document including its accuracy, fairness, completeness or verification or for any other statement made or purported to be made by any of them, or on behalf of them, and nothing in this document or at this presentation shall be relied upon as a promise or representation in this respect, whether as to the past or the future. The information and opinions contained in this presentation are current, and if not stated otherwise, as of the date of this presentation. The Company undertake no obligation to update or revise any information or the opinions expressed in this presentation as a result of new information, future events or otherwise. Any opinions or information expressed in this presentation are subject to change without notice.

This presentation does not constitute or form part of any offer or invitation or inducement to sell or issue, or any solicitation of any offer to purchase or subscribe for, any securities of RPG Life Sciences Limited Limited (the "Company"), nor shall it or any part of it or the fact of its distribution form the basis of, or be relied on in connection with, any contract or commitment, therefore. Any person/ party intending to provide finance / invest in the shares/businesses of the Company shall do so after seeking their own professional advice and after carrying out their own due diligence procedure to ensure that they are making an informed decision. This presentation is strictly confidential and may not be copied or disseminated, in whole or in part, and in any manner or for any purpose. No person is authorized to give any information or to make any representation not contained in or inconsistent with this presentation and if given or made, such information or representation must not be relied upon as having been authorized by any person. Failure to comply with this restriction may constitute a violation of the applicable securities laws. The distribution of this document in certain jurisdictions may be restricted by law and persons into whose possession this presentation comes should inform themselves about and observe any such restrictions. By participating in this presentation or by accepting any copy of the slides presented, you agree to be bound by the foregoing limitations.

RPG Group: Powered by Passion, Driven by Ethics

UNLEASH
TALENT
TOUCH
LIVES
OUTPERFORM
AND 😊

RPG Enterprises was founded in 1979. The group currently operates various businesses in Infrastructure, Technology, Life Sciences, Plantations and Tyre industries. The group has business history dating back to 1820 AD in banking, textiles, jute and tea. The Group grew in size and strength with several acquisitions in the 1980s and 1990s. RPG Group is one of India's fastest growing conglomerates with 31,000+ employees, presence in 135+ countries and annual gross revenues of USD 5.2 Bn



EPC major in infrastructure segments like T&D, Civil, Transportation, Oil & Gas, Renewables & Cables



One of India's leading tyre manufacturers



Global technology consulting and IT services company



Integrated pharma company in formulations and synthetic APIs




Technology solutions company catering to energy and infrastructure



One of India's largest plantation companies producing tea, rubber, etc.

RPG Life Sciences: An Integrated Pharmaceutical Company

RPG Life Sciences is an integrated research based pharmaceutical company operating in the domestic and international markets in the branded formulations, global generics and synthetic APIs space.



Domestic Formulations (DF)

Develop, manufacture and market branded formulations in India & Nepal

International Formulations (IF)

Develop, manufacture and market oral solid dosage formulations in the generics and branded generics space

APIs

Develop, manufacture and sell high value synthetic APIs in the general therapeutic category



Leader in Immunosuppressants



9 Therapies represented by High Equity Brands



50+ Markets Presence



3 Manufacturing Facilities



1300+ Employees

Strong 'Textbook' brands ; ↑ Chronic and Specialty therapies

Key Therapies

Nephrology

Rheumatology

Oncology

Pain Management

Gastroenterology

Neuropsychiatry

Cardio- Diabeto

Urology

DF Key Products

Legacy Portfolio

Immunosuppressants

Azoran

Azathioprine

Mofetyl

Mycophenolate Mofetil

Arpimune ME

Cyclosporine

Imunotac

Tacrolimus

Textbook Brands

Azoran

Azathioprine

Aldactone

Spironolactone

Lomotil

Diphenoxylate HCl

Naprosyn

Naproxen

Serenace

Haloperidol

Norpace New

Disopyramide Phosphate

Specialty

HerMab

Trastuzumab

Adlumab

Adalimumab

Ivzumab

Bevacizumab

Zestmab

Rituximab

T-JAKi

Tofacitinib

FC-IRO

Ferric Carboxymaltose

Denbri

Denosumab

New Portfolio

Chronic

SacuNew

Sacubitril+ Valsartan

NuGliptin

Vildagliptin

GliptiNext

Teneligliptin

DPO 510

Dapagliflozin

Solifirst

Solifenacin

MirasmarT S

More Smart...More Efficient!

Life Cycle Management
(Existing Products)

Azoran 75

Azathioprine 75 mg Tablets

Aldactone T

Aldactone 20 mg + Furosemide 20 mg Tablets

Aldactone F

Spironolactone 60 mg + Furosemide 20 mg

Naprosyn 250 +

Naproxen Sodium Tablet USP 275 mg + 550 mg

Naprosyn + Gel

THE PAIN RELIEF EXPERT

Naprosyn M

Sumatriptan & Naproxen Sodium Tablets

ROMILAST-BL

Romifen 100 mg and Sildenafil 25 mg Oral Suspension 7.5 mL

Tricaine Alma 2

Almogest 100 mg and Sildenafil 25 mg Oral Suspension 7.5 mL

IF Key Products

Generics - Azathioprine, Sodium Valproate PR, Nicorandil, Sertraline


Branded Generics – Siloxogene, Azoran, Mofetyl, Arpimmune ME, Dyzantil, Dipsope


APIs Key Products

Quinfamide, Azathioprine, Haloperidol, Risperidone, Propantheline Bromide, Nicorandil, Pantoprazole

Business Operations

Building a Strong-Consistent-Profitable Business



Bold Move 1 Galvanizing Organization to an “Inspiring Purpose”: Framing and embedding in the organisation

Bold Move 2 “Small Brands” to Building “Mega Brand of 100 cr +; future 500 cr OTC”: Naprosyn

Bold Move 3 “Small Product” to Building “Mega Rx Portfolio of 100 cr +; Potential 200 cr” : Immunosuppressants

Bold Move 4 “Small API” segment to Building “Formidable API Business”: Manthan

Bold Move 5 Predominant “Domestic Play” to “Expanded Global Play” : Capex infusion ~140 cr

Bold Move 6 “Operations” Focus to “Sustainable Operations” Focus: ESG

Multiple Projects targeted to Transform Business, ↓ Costs, ↑ Quality, Add New Business**1 Comprehensive Business Transformation Project****2 Plants Infra Modernization-Capacity Expansion Projects****3 COGS Reduction Projects****4 Product Re-engineering Projects****5 Quality Enhancement Projects****6 Innovation Projects****7 Digitalization Projects****8 M&A Projects****9 Med-tech Projects****10 ESG Projects****Project Charters, Workstreams, Scope, Review, KPIs Measurement**

3

Building Competitiveness :

3-4x SOV; Product Re-engineering; Profitable New Therapies entry from Day 1; Smart LCM; C3MP

SoV with ~ 90000 docs
up Manifold

RPG Serv: ↑ Customer Coverage, ↑ SoV, ↑ Engagement



Product Re-engineering

80% contributing DF 13 SKUs; 3 APIs

Smart Life cycle Management

Brands	New Combination	New Indication	New Patient Segment	New Dosage form	New Strength	New Customer/ Geography
Naprosyn	✓	✓	✓	✓		✓
Tricaine			✓	✓		✓
Aldactone	✓	✓	✓			✓
Serenace						✓
Lomotil						✓
Lomofen +	✓		✓	✓		✓
Azoran		✓	✓		✓	✓
ROMILAST	✓			✓		✓

Energizing Happy Teams: Happiness Framework

People Initiatives for building a happy performance focussed culture

I Feel Valued



You Excel. We Applaud.
Motivation continuum

I Love My Work



RPGLS Heroes
Outperformance
recognition

I am Growing



We Skill. You Grow.
Competency building
continuum



Akanksha
Career development

**High
Happiness Quotient**

I Live a Purposeful & Balanced Life



**RPGLS Values
Champions**
Living organizational
values

I Feel Connected



**RPGLS Happiness
Forums**
Leadership Connect –
Month & Quarter

I cherish our Culture



**RPGLS Parivar
Tyohar-Utsav
Shrankhla**
Digital RPGLS family
get- together


Financial Performance

Q1 FY26 Performance


(All figures in Rs. Crores)

Figures in circle are Margins


Revenue from Operations




EBITDA & EBITDA Margin



PBT & PBT Margin




PAT & PAT Margin



Q1 FY26: Business Segment-wise Performance


Business Segments



Domestic Formulations (DF)

Domestic Formulations contributed 69% to total sales of Q1 FY26


- Continue to deliver market beating growth this quarter as well
- New products contribution improving consistently on account of new launches in specialty & chronic segments and line extensions of legacy products
- Salesforce productivity consistently improving (currently >6 lakhs)
- Business driven by 5 Pillar strategy



International Formulations (IF)

International Formulations contributed 19% to total sales of Q1 FY26


- New Products/Customers/Markets contribution continues to improve
- Business driven by 4 Pillar strategy




API

API contributed 12% to total sales of Q1 FY26

- Growth impacted due to fire incident in one of the manufacturing blocks
- Continuous thrust on new customer development
- Business driven by 3 Pillar strategy



Key Financial Ratios Yearly Trends (ROCE, ROE, D/E)



Company continues to remain Debt-free

*Excluding impact of exceptional items: land assignment/fire; Including exceptional items, ROCE is 44.0%, ROE is 34.5%

RPG Life Sciences ICRA Rating Reaffirmation in FY25

A- (FY19) to A(FY21) to A+ (FY24)

Improvements recorded in ICRA Rating

- Long term rating reaffirmed at **A+** and outlook retained as stable
- Short term rating reaffirmed at **A1**



Factors affecting rating affirmation


- A robust capital structure and strong debt servicing indicators based on
 - Healthy cash flows
 - Company continues to remain debt-free
 - No debt-funded capital expenditure (capex)
- Steady growth in Top-line and improving operating margins
- Strong brands in the Indian Pharmaceutical Industry
- Expansion of product portfolio and geographical presence augur well for growth prospects

Business Strategy

Domestic Formulations (DF)

- Operating in Mass/Mass-specialty and Specialty segments
- Presence in both Acute & Chronic therapy areas
- Leading Textbook Brands – Azoran, Aldactone, Lomotil, Naprosyn, Serenace, Norpace
- Leading player in Immunosuppressant category
- Good Customer Coverage - Cardiologists, Diabetologists, Urologists, Nephrologists, Rheumatologists, Oncologists
- New Product Launches in New Category – Biosimilars as well as Chronic and Specialty segments

Business Strategy



18

International Formulations (IF) Business: Overview and Strategy

- Strong presence in immunosuppressant segment (Azathioprine)
- Footprints across Regulated and Emerging Markets - Canada, UK, Germany, France, Australia, South East Asia, Africa
- Long lasting, impeccable supply track record and business relationship with some of the leading generic players of the world
- High quality and process orientation making us a preferred partner
- Investments in plant upgradation and capacity expansion


Business Strategy



APIs Business: Business Strategy and Way Forward

- High value, low volume, niche APIs
- Mature stable molecules
- Provides backward integration to International Formulations business
- Footprints across geographies - LATAM, Germany, China, South Korea, Iran, Bangladesh, Egypt, India, etc.
- Strong customer focus – long-lasting relationship with big pharma and leading generic firms.

Business Strategy



Infrastructure Capabilities & ESG Initiatives

Manufacturing Facilities

Formulations Unit 1, Ankleshwar



- F1 unit caters to the domestic and emerging markets
- Multipurpose plant with dedicated product lines for oral dosage forms including tablets, liquids and powder
- WHO, Kenya, Nigeria approved
- Modernization cum Capacity Expansion underway

Formulations Unit 2, Ankleshwar



- F2 unit caters to the regulated markets
- Dedicated product lines for oral dosage (capsules & tablets)
- Equipped to handle low RH and low temperature conditions products
- WHO, EUGMP (from Hamburg Health authority), Canada, Ethiopia, Kenya, Sudan, Nigeria approved
- Modernization cum Capacity Expansion underway

API Unit, Navi Mumbai



- MF2: Dedicated immunosuppressant facility for regulated and emerging markets including India
- MF3: Multipurpose unit catering to regulated and emerging markets including India
- MF4: Multipurpose unit catering to emerging markets including India
- WHO, TGA Australia approved & Written Confirmation (WC) received from CDSCO
- Approved by WHO GMP from Food and Drug Control Administration (FDCA) – Maharashtra, TGA (Australia), PMDA (Japan)
- Modernization cum Capacity Expansion underway

Digital Initiatives: Manufacturing and Quality



Digital Retina Scanner

- Biometric Access with IRIS/ Retina Scanner enables consistency of electronic records and signatures
- Access to only qualified professionals, Batch Management, Recipe Management, Audit logs

Intelligent Chilling Plant Manager

- Implementation of Utility Asset Management Systems with access over IoT, supported by Customized Algorithms for Efficient Monitoring, Control & Analytics

IOT based AHU monitoring system

- Operates Pumps & Chillers according to Operating Hours to maintain equal run time
- Automatically change over Working pump to Standby if Pump fails during operation

Power Management System

- Safe, reliable, efficient, and compliant operation of electrical distribution systems, and connected assets enabling at all times

Quality Functions

e-QMS: Digital platform to track all 6 quality parameters

e-DMS: Digital platform to manage manufacturing/quality documents








e-LMS: Digital platform to track training sessions on CGMP

ESG FY25 update

	Initiatives	FY25
Environmental	<ul style="list-style-type: none"> • Carbon emission reduction • Energy Efficiency: Pumps; Chillers/Brine Plant; Leakages rectification • Water Management: Recycling of STP water; Rainwater harvesting • Waste Management: No landfill waste generation 	<p>↓ FY24 : 26.8% ; FY25: 41.2 %</p> <p>↑ FY24: 26% ; FY25 : 41.0 %</p> <p>↓ FY 24: 6% ; FY25 : 7.0 %</p> <p>↓ FY24: 49% ; FY25 : 52.0 %</p>
Social	<ul style="list-style-type: none"> • Product Responsibility- Adherence to stipulated mandates • Diversity- women deployment, occupational health • Tree Plantation • Employee Well-being: Comorbidity tracking 	<p>Strict Quality vigil through Manthan 3 Project</p> <p>↑ to 6.3% from 4.8%</p> <p>100+ trees planted</p> <p>Done for all factory employees</p>
Governance	<ul style="list-style-type: none"> • Data Integrity: Digital initiatives e.g. e-QMS, e-DMS, e-LMS • Cybersecurity: IT assets security through EDR tool • Best Practices/Systems and Processes across functions 	<p>Implemented at Ankleshwar; Navi Mumbai</p> <p>Implemented</p> <p>Sales & Marketing</p>

Journey Ahead

RPGLS Journey Ahead: 7 strategic pillars of action

1		Portfolio development and mega-brands building	<ul style="list-style-type: none">• Project underway to grow our immunosuppressant portfolio to 200+ crores• Focused initiatives to grow Naprosyn to a 100+ crores brand; building our MABs portfolio
2		Growing our API business	<ul style="list-style-type: none">• Focus on new geographies, new launch pipeline and enhancing manufacturing productivity• Focus on strengthening customer relationships and onboarding new high-value customers
3		Strong Digital Roadmap	<ul style="list-style-type: none">• Multiple digital initiatives designed to streamline front-end and backend operations• Initiatives focus on improving efficiency & compliance, reducing costs and growing topline
4		Mergers & Acquisitions	<ul style="list-style-type: none">• M&A Framework with criteria defined - target therapies, brands• Evaluation of multiple proposals underway to identify opportunities for growth synergy
5		New products across segments, new therapies	<ul style="list-style-type: none">• Focused new product pipeline; lab modernization and org expansion complete• Strategy to evaluate and expand into adjacencies in RPGLS strength therapies
6		State-of-art capacity plants	<ul style="list-style-type: none">• 140 crores capex infused since FY22 helped build modern plant with EU, TGA, PMDA, etc. approval• Evaluation ongoing of varied opportunities for improving manufacturing productivity
7		Talent Development /Acquisition	<ul style="list-style-type: none">• Org structure review & role/skill-gaps identification for strengthening• Talent development and talent acquisition across all key business and support functions

THANK YOU